Free tool
FAERS Monitor: Kineret
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103950 or its brand name (Kineret, Anakinra). Reports on generic versions are filed under their own applications.
Reports
16,900
Serious
11,721
69% of reports
Hospitalization
5,311
Death reported
1,576
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use5,297
- drug ineffective4,355
- condition aggravated1,743
- pain1,603
- rheumatoid arthritis1,556
- arthralgia1,207
- joint swelling1,192
- pyrexia1,189
- drug intolerance1,168
- injection site pain1,047
- rash996
- nausea961
- product dose omission issue940
- infection921
- vomiting884
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 118 |
| 2005 | 58 |
| 2006 | 111 |
| 2007 | 253 |
| 2008 | 276 |
| 2009 | 88 |
| 2010 | 75 |
| 2011 | 80 |
| 2012 | 109 |
| 2013 | 117 |
| 2014 | 107 |
| 2015 | 186 |
| 2016 | 563 |
| 2017 | 864 |
| 2018 | 1,078 |
| 2019 | 1,586 |
| 2020 | 3,066 |
| 2021 | 1,624 |
| 2022 | 1,845 |
| 2023 | 1,210 |
| 2024 | 1,289 |
| 2025 | 1,182 |
| 2026 | 1,015 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,259 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 1,556 | 17.3 | 16.5 | 23,651 |
| drug intoleranceSignal | 1,168 | 15.2 | 14.4 | 15,386 |
| joint swellingSignal | 1,192 | 12.4 | 11.7 | 12,432 |
| infectionSignal | 921 | 8.0 | 7.5 | 5,604 |
| off label useSignal | 5,297 | 7.6 | 7.4 | 31,310 |
| condition aggravatedSignal | 1,743 | 7.2 | 6.9 | 9,331 |
| pyrexiaSignal | 1,189 | 4.3 | 4.1 | 3,034 |
| injection site painSignal | 1,047 | 4.3 | 4.0 | 2,637 |
| drug ineffectiveSignal | 4,355 | 4.1 | 4.0 | 10,950 |
| product dose omission issueSignal | 940 | 4.0 | 3.7 | 2,124 |
| arthralgiaSignal | 1,207 | 3.6 | 3.4 | 2,326 |
| painSignal | 1,603 | 3.3 | 3.1 | 2,568 |
| rashSignal | 996 | 2.8 | 2.7 | 1,215 |
| vomitingSignal | 884 | 2.3 | 2.2 | 693 |
| nausea | 961 | 1.5 | 1.4 | 172 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.